Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
K Xu, E Bastia, M Schwarzschild - Pharmacology & therapeutics, 2005 - Elsevier
In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A 2A
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …
[HTML][HTML] Nitric oxide (NO): an emerging target for the treatment of glaucoma
…, F Impagnatiello, E Ongini, E Bastia - … & visual science, 2014 - tvst.arvojournals.org
The predominant risk factor for the progression of glaucoma is an increase in IOP, mediated
via a reduction in aqueous outflow through the conventional (trabecular meshwork and …
via a reduction in aqueous outflow through the conventional (trabecular meshwork and …
Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
F Impagnatiello, E Bastia, N Almirante… - British Journal of …, 2019 - Wiley Online Library
In patients with ocular hypertension or glaucoma, all treatments aim to lower intraocular
pressure (IOP) by modulating aqueous humour (AH) production and/or uveoscleral and …
pressure (IOP) by modulating aqueous humour (AH) production and/or uveoscleral and …
Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32
AW Dunah, AC Sirianni, AA Fienberg, E Bastia… - Molecular …, 2004 - ASPET
Interactions between dopaminergic and glutamatergic systems in the striatum are thought to
underlie both the symptoms and adverse effects of treatment of Parkinson's disease. We …
underlie both the symptoms and adverse effects of treatment of Parkinson's disease. We …
[HTML][HTML] A crucial role for forebrain adenosine A2A receptors in amphetamine sensitization
E Bastia, YH Xu, AC Scibelli, YJ Day, J Linden… - …, 2005 - nature.com
Adenosine A 2A receptors (A 2A Rs) are well positioned to influence the maladaptive CNS
responses to repeated dopaminergic stimulation in psychostimulant addiction. Expression of …
responses to repeated dopaminergic stimulation in psychostimulant addiction. Expression of …
A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma
V Borghi, E Bastia, M Guzzetta, V Chiroli… - Journal of ocular …, 2010 - liebertpub.com
Purpose: Nitric oxide (NO) is involved in a variety of physiological processes including ocular
aqueous humor dynamics by targeting mechanisms that are complementary to those of …
aqueous humor dynamics by targeting mechanisms that are complementary to those of …
Forebrain adenosine A2A receptors contribute to L-3, 4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice
D Xiao, E Bastia, YH Xu, CL Benn, JHJ Cha… - Journal of …, 2006 - Soc Neuroscience
Adenosine A 2A receptor antagonists provide a promising nondopaminergic approach to the
treatment of Parkinson's disease (PD). Initial clinical trials of A 2A antagonists targeted PD …
treatment of Parkinson's disease (PD). Initial clinical trials of A 2A antagonists targeted PD …
Effects of A1 and A2A adenosine receptor ligands in mouse acute models of pain
E Bastia, K Varani, A Monopoli, R Bertorelli - Neuroscience letters, 2002 - Elsevier
The effects of selective A 1 and A 2A adenosine receptor compounds in two mouse models
of acute nociception were studied: acetic acid-induced writhing and the hot plate assays. …
of acute nociception were studied: acetic acid-induced writhing and the hot plate assays. …
[HTML][HTML] Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization
…, R Moratalla, L Yu, AB Martín, K Xu, E Bastia… - …, 2003 - nature.com
Repeated treatment with the psychostimulant amphetamine produces behavioral sensitization
that may represent the neural adaptations underlying some features of psychosis and …
that may represent the neural adaptations underlying some features of psychosis and …
[HTML][HTML] Intraocular pressure–lowering activity of NCX 470, a novel nitric oxide–donating bimatoprost in preclinical models
…, G Prasanna, V Borghi, E Bastia… - … & Visual Science, 2015 - iovs.arvojournals.org
Purpose: The prostaglandin F2alpha (PGF2α) analogue bimatoprost lowers intraocular
pressure (IOP) by increasing uveoscleral outflow at doses shown to elicit redness of the eye. …
pressure (IOP) by increasing uveoscleral outflow at doses shown to elicit redness of the eye. …